Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BioAge Labs, Inc. is a clinical-stage biotechnology company focused on the discovery and development of therapeutics targeting the biology of human aging to treat age-related diseases. The company operates within the biotechnology and pharmaceutical research industries, with a primary emphasis on leveraging human longevity data to identify novel drug targets. Its core revenue drivers are research collaborations, pipeline advancement toward clinical milestones, and capital raised through public and private financing rather than commercial product sales.
Founded in 2015, BioAge Labs evolved from an academic-data-driven research effort into a vertically integrated drug discovery and development company. Its strategy centers on using large-scale human cohort datasets and machine learning to identify molecular drivers of aging-related conditions, which the company believes provides a competitive advantage over traditional target discovery approaches. BioAge primarily serves pharmaceutical partners, investors, and, ultimately, patient populations affected by chronic and age-associated diseases such as neurodegeneration, metabolic disorders, and immune dysfunction.
Business Operations
BioAge Labs generates value through its drug discovery and development operations, which encompass target identification, preclinical research, and early-stage clinical development. The company’s operating model integrates proprietary computational biology platforms with in-house laboratory validation, enabling it to progress multiple therapeutic programs simultaneously. Revenue to date has primarily been derived from strategic collaborations, upfront payments, and research funding rather than product commercialization.
Operations are primarily based in the United States, with research activities supported by proprietary datasets, licensed biological samples, and internally developed analytics technologies. BioAge maintains full or shared rights to its core therapeutic programs and selectively enters into partnerships to advance development, manage risk, and access complementary capabilities. The company does not currently rely on manufacturing assets, instead using third-party providers for preclinical and clinical supply needs.
Strategic Position & Investments
BioAge’s strategic direction is focused on advancing its pipeline of aging-targeted therapeutics into and through clinical trials, while continuing to expand its discovery platform. Growth initiatives include prioritizing indications with clear biological links to aging, accelerating lead programs, and pursuing selective collaborations with larger pharmaceutical companies. The company has invested significantly in data infrastructure and translational research capabilities to support this strategy.
The company’s portfolio consists of internally developed drug candidates rather than a collection of acquired operating businesses. BioAge has not historically pursued large-scale acquisitions but instead emphasizes internal R&D investment and targeted licensing arrangements. Emerging areas of focus include immune aging, metabolic regulation, and neuroinflammation, which the company views as high-impact sectors with substantial unmet medical need.
Geographic Footprint
BioAge Labs is headquartered in the United States, with its principal offices and research operations located in California. Its activities are primarily concentrated in North America, reflecting its reliance on U.S.-based talent, clinical research infrastructure, and regulatory pathways. The company’s public listing and capital markets activities are also centered in the United States.
While BioAge does not maintain significant physical operations outside the U.S., its research incorporates global human longevity datasets, and its clinical development strategy anticipates international trial sites as programs advance. Through collaborations and data access agreements, the company maintains an indirect operational and scientific footprint across Europe and other regions with established population health studies.
Leadership & Governance
BioAge Labs was founded by scientists with expertise in computational biology and aging research, and its leadership emphasizes data-driven decision-making, scientific rigor, and capital discipline. The company’s governance and management philosophy centers on translating insights from human biology into clinically meaningful therapies while maintaining a focused and efficient operating structure.
Key executives include:
- Kristen Fortney, PhD – Chief Executive Officer
- Eric Dishman, PhD – Chief Science Officer
The leadership team collectively brings experience in biotechnology research, translational medicine, and strategic partnerships. Information on additional executive roles is limited in publicly available sources; data inconclusive based on available public sources.